INOVIO Reports Third Quarter 2026 Financial Results and Recent
INOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights • VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in
How this was made
The 30-second read
Why it matters
The FDA's accelerated approval of VOCERYQ and the $80.5M public offering provide a clear catalyst for near‑term stock movement.
Market read
The approval and capital raise are material events for INOVIO, likely driving short‑term price action.
What to watch
Potential reimbursement challenges and the need for post‑approval sales data could temper upside.
Inovio reports Q3 2026 net loss of $49.2 million, or $0.50 per share, after FDA accelerated approval of VOCERYQ
Operating expenses fell year over year and the company now has an approved product, but Q3 revenue was $298,901, the net loss widened to $49.2 million from $45.5 million (a non-cash warrant fair value loss is the company's stated main driver), and cash, cash equivalents and short-term investments were $48.4 million before the November 2026 offering.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue from collaborative arrangements, three months ended Sep 30, 2026GAAP | $298,901 | – | – |
| Revenue from collaborative arrangements, nine months ended Sep 30, 2026GAAP | $298,901 | – | – |
| Research and development expenses, three months ended Sep 30, 2026GAAP | $10,618,018 | – | – |
| Selling, general and administrative expenses, three months ended Sep 30, 2026GAAP | $9,205,813 | – | – |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $19,823,831 | – | – |
| Loss from operations, three months ended Sep 30, 2026GAAP | $(19,524,930) | – | – |
| Interest income, three months ended Sep 30, 2026GAAP | $356,148 | – | – |
| Change in fair value of common stock warrant liabilities, three months ended Sep 30, 2026GAAP | $(26,938,975) | – | – |
| Loss on investment in affiliated entity, three months ended Sep 30, 2026GAAP | — | – | – |
| Net unrealized gain on available-for-sale equity securities, three months ended Sep 30, 2026GAAP | $129,308 | – | – |
| Other expense, net, three months ended Sep 30, 2026GAAP | $(3,226,340) | – | – |
| Net loss, three months ended Sep 30, 2026GAAP | $(49,204,789) | – | – |
| Net loss per share, basic and diluted, three months ended Sep 30, 2026GAAP | $(0.50) | – | – |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $35,514,674 | – | – |
| Selling, general and administrative expenses, nine months ended Sep 30, 2026GAAP | $24,883,672 | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $60,398,346 | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | $(60,099,445) | – | – |
| Interest income, nine months ended Sep 30, 2026GAAP | $1,159,588 | – | – |
| Change in fair value of common stock warrant liabilities, nine months ended Sep 30, 2026GAAP | $(8,932,656) | – | – |
| Loss on investment in affiliated entity, nine months ended Sep 30, 2026GAAP | $(2,103,688) | – | – |
| Net unrealized gain on available-for-sale equity securities, nine months ended Sep 30, 2026GAAP | $302,606 | – | – |
| Other expense, net, nine months ended Sep 30, 2026GAAP | $(5,226,450) | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | $(74,900,045) | – | – |
| Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(0.90) | – | – |
| Cash, cash equivalents and short-term investments, as of Sep 30, 2026 (excluding net proceeds from the November 2026 offering)other | $48.4M | – | – |
| Total assets, as of Sep 30, 2026GAAP | $60,136,243 | – | – |
| Total Inovio Pharmaceuticals, Inc. stockholders' equity (deficit), as of Sep 30, 2026GAAP | $(33,922,972) | – | – |
Cash runway: into late fourth quarter 2027 (company estimate) outlook
- NoteOperational net cash burn estimate of approximately $21.0 million for the fourth quarter of 2026
- NoteRunway includes net proceeds of approximately $80.5 million from the public offering in November 2026
- NoteRunway includes $10.9 million in proceeds from warrant exercises subsequent to September 30, 2026
- NoteRunway does not include revenues from sales of VOCERYQ expected to commence in 2027 or any further capital-raising activities
What drove it
- Company states that the R&D decrease to $10.6 million from $13.3 million was primarily the result of lower engineering outside services related to device development and lower employee and consultant compensation, including stock-based compensation, among other variances.
- Company states that the SG&A increase to $9.2 million from $7.9 million was due to the anticipated launch of VOCERYQ.
- Company states that the increase in net loss to $49.2 million from $45.5 million was primarily driven by a $26.9 million non-cash loss on fair value adjustment related to warrant liabilities, compared with a $22.5 million non-cash loss in the same period of 2025.
- Company states that the fair value of the warrants fluctuates with its share price and other market inputs, and that this adjustment can result in significant variability in reported net loss.
- FDA granted accelerated approval for VOCERYQ on October 30, 2026, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis, based on complete response in the RRP-001 study of 32 adult patients.
- Company expects VOCERYQ to be available to order and ship in approximately 60 days from the approval date, with full field deployment in the first quarter of 2027, and it has engaged Syneos Health for field team recruitment and deployment.
Concerns
- Q3 2026 net loss widened to $(49,204,789) from $(45,496,672), and the nine-month net loss narrowed to $(74,900,045) from $(88,710,781); the company attributes the quarterly change mainly to the warrant fair value loss.
- Change in fair value of common stock warrant liabilities was $(26,938,975) for Q3 2026 and the company states that this line can cause significant variability in reported net loss.
- Revenue from collaborative arrangements was $298,901 in Q3 2026 and was not reported in the prior-year quarter ($—); the release gives no product revenue figure.
- Cash, cash equivalents and short-term investments were $48.4 million as of September 30, 2026, versus $58.5 million at December 31, 2025, before the November 2026 offering.
- Company states the cash runway excludes VOCERYQ revenues and assumes an estimated Q4 2026 net cash burn of approximately $21.0 million.
- Weighted average common shares used for net loss per share rose to 98,633,024 in Q3 2026 from 52,168,694 in Q3 2025, and the company describes further capital raising as possible.
What to watch
- Timing of VOCERYQ order and shipment, about 60 days from the October 30, 2026 approval date, and the pace of full field deployment in the first quarter of 2027.
- Submission of the confirmatory study draft protocol to FDA by the end of 2026 and alignment on a final protocol by mid-2027, since continued approval may depend on verification of clinical benefit.
- Planned submission of a conditional marketing authorization application for VOCERYQ in Europe before the end of 2026.
- Fair value movements in the common stock warrant liabilities, which the company links to its share price and market inputs, and warrant exercise proceeds of $10.9 million after September 30, 2026.
- Discussions with potential partners for the DPROT platform and rare disease indications including Hemophilia A, Fabry Disease and HPP.
- Actual net cash burn versus the estimated approximately $21.0 million for Q4 2026, and whether the runway into late fourth quarter 2027 holds.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were $48.4 million as of September 30, 2026 (excluding net proceeds from the November 2026 offering), compared with $58.5 million as of December 31, 2025.
- Balance sheet as of September 30, 2026: cash and cash equivalents $46,962,549; short-term investments 1,398,734; total assets $60,136,243; common stock warrant liabilities 70,011,676 (current liabilities total 89,466,997); total liabilities 94,059,215; total Inovio stockholders' equity (deficit) $(33,922,972).
- Balance sheet as of December 31, 2025: cash and cash equivalents $44,273,319; short-term investments 14,239,145; total assets $74,310,035; common stock warrant liabilities 29,067,162; total liabilities 50,213,759; total Inovio stockholders' equity $24,096,276.
- Net proceeds of approximately $80.5 million from the public offering completed in November 2026 are described as supporting the commercial launch of VOCERYQ.
- Company states that the cash runway projection does not include VOCERYQ sales revenue or further capital raises.
Analysis
Inovio reports Q3 2026 results that reflect the transition from a development-stage company to one with an FDA-approved product. VOCERYQ received accelerated approval on October 30, 2026 for reducing the frequency of surgical papilloma excisions in adults with RRP. Reported revenue is limited to revenue from collaborative arrangements of $298,901 in the quarter, against $— in the prior-year quarter, and $298,901 for the nine months against $65,343 a year earlier. The release does not report any product sales, and it states that cash runway projections do not include VOCERYQ revenues expected to commence in 2027.
Cost trends are mixed. Research and development fell to $10,618,018 from $13,333,329 in Q3, and the company attributes this mainly to lower engineering outside services related to device development and lower employee and consultant compensation. Selling, general and administrative expense rose to $9,205,813 from $7,877,126, which the company ties to the anticipated VOCERYQ launch. Total operating expenses were $19,823,831 against $21,210,455, and the loss from operations narrowed to $(19,524,930) from $(21,210,455). For the nine months, total operating expenses fell to $60,398,346 from $69,410,846.
Below operating loss, the result is dominated by the change in fair value of common stock warrant liabilities, which was a loss of $(26,938,975) in Q3 2026 against $(22,515,730) a year earlier. The company states that the net loss increase to $(49,204,789) from $(45,496,672) was primarily driven by this non-cash item and that warrant values move with its share price and market inputs. Net loss per share was $(0.50) against $(0.87), a per-share improvement that the release does not explain in detail. Weighted average shares rose to 98,633,024 from 52,168,694, which the release does not explain. Other expense, net was $(3,226,340) against $(1,938,236).
On liquidity, cash, cash equivalents and short-term investments were $48.4 million at September 30, 2026, against $58.5 million at December 31, 2025, before the November 2026 offering. The company reports net offering proceeds of approximately $80.5 million, $10.9 million of warrant exercise proceeds after quarter end, and an estimated Q4 2026 operational net cash burn of approximately $21.0 million. On that basis it expects cash to support operations into late fourth quarter 2027, past the VOCERYQ launch. Total assets were $60,136,243 and total Inovio stockholders' equity was $(33,922,972) at September 30, 2026. Common stock warrant liabilities rose to 70,011,676 from 29,067,162 at December 31, 2025, which the release does not directly explain.
The release gives no formal revenue, margin or expense guidance, and no prior-period outlook was supplied for comparison. The key items for a reader are the launch timeline (shipping about 60 days after approval, full field deployment in Q1 2027), the confirmatory study protocol milestones, the European filing before year end, and the sensitivity of reported net loss to warrant fair value changes.
Management, verbatim
We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients
Dr. Jacqueline Shea, President and Chief Executive Officer
Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline
Dr. Jacqueline Shea, President and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) figures for all income statement lines, so no quarter-over-quarter changes are reported
- Percentage changes year over year for all lines; the release describes direction only
- Prior-year and prior-quarter comparisons for total assets, cash and stockholders' equity as printed for the same line; the release compares cash only to December 31, 2025
- Product revenue or VOCERYQ sales figures; none are reported in the release
- Gross margin, cost of sales and tax lines; none are presented
- Operating cash flow and free cash flow for Q3 2026 and the nine months
- Capital returns (share repurchases or dividends); none are reported
- Formal financial guidance for revenue, gross margin, operating expenses or tax rate; only the cash runway and Q4 2026 cash burn estimate are given
- Prior guidance for vs_prior_guidance comparison; no previous outlook was provided
- Segment or geographic revenue breakdown; none is reported
- Explanation of the reduction in net loss per share and the increase in weighted average shares
- Net proceeds from the November 2026 offering in the balance sheet as of September 30, 2026 (the release gives approximately $80.5 million only as a post-quarter figure)
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
INOVIO (NASDAQ: INO) is a commercial‑stage biotech focused on DNA medicines for HPV‑related diseases.
Ticker impact
INOVIO received FDA accelerated approval for VOCERYQ and reported Q3 2026 results, including an $80.5M public offering.
likely upward pressure as market prices in the approval and funding.
First disclosure of a groundbreaking FDA approval for a DNA medicine and a sizable equity raise, both material for a commercial-stage biotech.
Market effects
Strengthens the DNA‑medicine sector and may lift peers developing similar platforms.
Positive for US biotech investors, modest effect on broader market.
Highlights FDA's role in advancing novel therapeutics, may attract global biotech interest.
Counterpoint
If the market has already priced in the approval, the stock may face short‑term profit‑taking.
Key entities
- productVOCERYQ
First FDA‑approved DNA medicine for recurrent respiratory papillomatosis.
- regulatorFDA
U.S. Food and Drug Administration granting accelerated approval.
